Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Investigation of the safety of topical metronidazole from a pharmacokinetic perspective.

Iida J, Kudo T, Shimada K, Yatsuno Y, Yamagishi S, Hasegawa S, Ike H, Sato T, Kagaya H, Ito K.

Biol Pharm Bull. 2013;36(1):89-95.

2.

Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes.

Kudo T, Endo Y, Taguchi R, Yatsu M, Ito K.

Xenobiotica. 2015 May;45(5):413-9. doi: 10.3109/00498254.2014.990948. Erratum in: Xenobiotica. 2015 May;45(5):464.

PMID:
25470432
3.
5.

In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties.

Yu M, Ma H, Lei M, Li N, Tan F.

Eur J Pharm Biopharm. 2014 Sep;88(1):92-103. doi: 10.1016/j.ejpb.2014.03.019.

PMID:
24704200
6.

Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers.

Yamazaki H, Shimada T.

Biochem Pharmacol. 1997 Dec 1;54(11):1195-203.

PMID:
9416970
7.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
8.

Concentrations of metronidazole in human plasma and saliva after tablet or gel administration.

de C Bergamaschi C, Berto LA, Venâncio PC, Cogo K, Franz-Montan M, Motta RH, Santamaria MP, Groppo FC.

J Pharm Pharmacol. 2014 Jan;66(1):40-7. doi: 10.1111/jphp.12161.

PMID:
24341948
9.

Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.

Hasegawa M, Tahara H, Inoue R, Kakuni M, Tateno C, Ushiki J.

Drug Metab Dispos. 2012 Mar;40(3):474-80. doi: 10.1124/dmd.111.042754.

10.

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.

Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Kärkkäinen P.

Hepatology. 2004 Dec;40(6):1379-86.

PMID:
15565569
11.

mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.

Graham MJ, Bell AR, Crewe HK, Moorcraft CL, Walker L, Whittaker EF, Lennard MS.

Xenobiotica. 2003 Mar;33(3):225-37.

PMID:
12637241
12.

Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation.

Hosoi Y, Uno Y, Murayama N, Fujino H, Shukuya M, Iwasaki K, Shimizu M, Utoh M, Yamazaki H.

Biochem Pharmacol. 2012 Dec 15;84(12):1691-5. doi: 10.1016/j.bcp.2012.09.026.

PMID:
23041648
14.

Use of metronidazole gel to control malodor in advanced and recurrent breast cancer.

Kuge S, Tokuda Y, Ohta M, Okumura A, Kubota M, Ninomiya S, Sawamura S, Makuuchi H, Tajima T, Mitomi T.

Jpn J Clin Oncol. 1996 Aug;26(4):207-10.

PMID:
8765176
15.

In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.

Yamaori S, Takami K, Shiozawa A, Sakuyama K, Matsuzawa N, Ohmori S.

Biol Pharm Bull. 2015;38(3):441-7. doi: 10.1248/bpb.b14-00711.

16.

In vitro and in vivo evaluation of Assam Bora rice starch-based bioadhesive microsphere as a drug carrier for colon targeting.

Ahmad MZ, Akhter S, Ahmad I, Singh A, Anwar M, Shamim M, Ahmad FJ.

Expert Opin Drug Deliv. 2012 Feb;9(2):141-9. doi: 10.1517/17425247.2012.633507.

PMID:
22236045
17.

Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.

Morioka Y, Nishimura M, Imai T, Suzuki S, Harada M, Satoh T, Naito S.

Drug Metab Pharmacokinet. 2006 Feb;21(1):19-28.

18.

Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.

Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L.

Br J Clin Pharmacol. 2010 Feb;69(2):193-9. doi: 10.1111/j.1365-2125.2009.03572.x.

19.

Synthesis and evaluation of sulfate conjugated metronidazole as a colon-specific prodrug of metronidazole.

Kim H, Lee Y, Yoo H, Kim J, Kong H, Yoon JH, Jung Y, Kim YM.

J Drug Target. 2012 Apr;20(3):255-63. doi: 10.3109/1061186X.2011.639024.

PMID:
22118327
20.

Diosmin pretreatment affects bioavailability of metronidazole.

Rajnarayana K, Reddy MS, Krishna DR.

Eur J Clin Pharmacol. 2003 Apr;58(12):803-7.

PMID:
12698306

Supplemental Content

Support Center